Number of patients | 10 |
Age (mean ± SD) | 65.30 ± 9.67 |
Gender | Female |
Cancer type | Ovarian cancer |
BMI (Kg/m2) (mean ± SD) | 25.16 ± 8.86 |
ECOG | Â |
 0 | 6 (60%) |
 1 | 2 (20%) |
 2 | 1 (10%) |
 3 | 1 (10%) |
Histology | Â |
 High-grade serous carcinoma | 8 (80%) |
 Low-grade serous carcinoma | 1 (10%) |
 Clear cell carcinoma | 1 (10%) |
Federation of gynecology and obstetrics stage (FIGO) | Â |
 Stage II | 1 (10%) |
 Stage III | 6 (60%) |
 Stage IV | 3 (30%) |
T Stage | Â |
 T2 | 1 (10%) |
 T3 | 7 (70%) |
 Tx | 2 (20%) |
N Stage | Â |
 N0 | 3 (30%) |
 N1 | 5 (50%) |
 Nx | 2 (20%) |
M Stage | Â |
 M0 | 4 (40%) |
 M1 | 2 (20%) |
 Mx | 4 (40%) |
Primary surgery | Â |
 Stage II | 1 (100%) |
 Stage III | 5 (83%) |
 Stage IV | 2 (66%) |
Residual disease | Â |
 Stage II | R0: 1 (100%) |
 Stage III | R0: 2 (33%), R1: 3 (60%), R2: 1 (17%) |
 Stage IV | R2: 3 (100%) |